Ivosidenib

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer.

Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells. Ivosidenib was approved for medical use in the United States in July 2018, and in the European Union in May 2023.

The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1328963904 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

18 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.